Moxetumomab Pasudotox
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Hairy Cell Leukemia
Conditions
Relapsed/Refractory Hairy Cell Leukemia
Trial Timeline
— → —
NCT ID
NCT03501615About Moxetumomab Pasudotox
Moxetumomab Pasudotox is a pre-clinical stage product being developed by AstraZeneca for Relapsed/Refractory Hairy Cell Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03501615. Target conditions include Relapsed/Refractory Hairy Cell Leukemia.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Hairy Cell Leukemia were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03501615 | Pre-clinical | Completed |
Competing Products
20 competing products in Relapsed/Refractory Hairy Cell Leukemia